Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype

REFERENCES

1. 1.↵
   2. Louis DN,
   3. Perry A,
   4. Reifenberger G, et al

   . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

   CrossRefPubMed
2. 2.↵
   2. Yan H,
   3. Parsons DW,
   4. Jin G, et al

   . IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73 doi:10.1056/NEJMoa0808710 pmid:19228619

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Brat DJ,
   3. Verhaak RG,
   4. Aldape KD, et al

   ; Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481–98 doi:10.1056/NEJMoa1402121 pmid:26061751

   CrossRefPubMed
4. 4.↵
   2. Eckel-Passow JE,
   3. Lachance DH,
   4. Molinaro AM, et al

   . Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015;372:2499–508 doi:10.1056/NEJMoa1407279 pmid:26061753

   CrossRefPubMed
5. 5.↵
   2. Ceccarelli M,
   3. Barthel FP,
   4. Malta TM, et al

   . Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 2016;164:550–63 doi:10.1016/j.cell.2015.12.028 pmid:26824661

   CrossRefPubMed
6. 6.↵
   2. Cairncross G,
   3. Wang M,
   4. Shaw E, et al

   . Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337–43 doi:10.1200/JCO.2012.43.2674 pmid:23071247

   Abstract/FREE Full Text
7. 7.↵
   2. van den Bent MJ,
   3. Brandes AA,
   4. Taphoorn MJ, et al

   . Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31:344–50 doi:10.1200/JCO.2012.43.2229 pmid:23071237

   Abstract/FREE Full Text
8. 8.↵
   2. Di Carlo DT,
   3. Duffau H,
   4. Cagnazzo F, et al

   . IDH wild-type WHO grade II diffuse low-grade gliomas: a heterogeneous family with different outcomes—systematic review and meta-analysis. Neurosurg Rev 2018 Jun 26. [Epub ahead of print] doi:10.1007/s10143-018-0996-3 pmid:29943141

   CrossRefPubMed
9. 9.↵
   2. Aibaidula A,
   3. Chan AK,
   4. Shi Z, et al

   . Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 2017;19:1327–37 doi:10.1093/neuonc/nox078 pmid:28575485

   CrossRefPubMed
10. 10.↵
    2. Poulen G,
    3. Goze C,
    4. Rigau V, et al

    . Huge heterogeneity in survival in a subset of adult patients with resected, wild-type isocitrate dehydrogenase status, WHO grade II astrocytomas. J Neurosurg 2018 Apr 20:1–10. [Epub ahead of print] doi:10.3171/2017.10.JNS171825 pmid:29676695

    CrossRefPubMed
11. 11.↵
    2. Brat DJ,
    3. Aldape K,
    4. Colman H, et al

    . cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol 2018;136:805–10 doi:10.1007/s00401-018-1913-0 pmid:30259105

    CrossRefPubMed
12. 12.↵
    2. Hervey-Jumper SL,
    3. Berger MS

    . Evidence for improving outcome through extent of resection. Neurosurg Clin N Am 2019;30:85–93 doi:10.1016/j.nec.2018.08.005 pmid:30470408

    CrossRefPubMed
13. 13.↵
    2. Smith JS,
    3. Chang EF,
    4. Lamborn KR, et al

    . Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008;26:1338–45 doi:10.1200/JCO.2007.13.9337 pmid:18323558

    Abstract/FREE Full Text
14. 14.↵
    2. Ius T,
    3. Isola M,
    4. Budai R, et al

    . Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival—a single-institution experience in 190 patients: clinical article. J Neurosurg 2012;117:1039–52 doi:10.3171/2012.8.JNS12393 pmid:23039150

    CrossRefPubMedWeb of Science
15. 15.↵
    2. McGirt MJ,
    3. Chaichana KL,
    4. Attenello FJ, et al

    . Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63:700–07; author reply 707–08 doi:10.1227/01.NEU.0000325729.41085.73 pmid:18981880

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Roelz R,
    3. Strohmaier D,
    4. Jabbarli R, et al

    . Residual tumor volume as best outcome predictor in low grade glioma: a nine-years near-randomized survey of surgery vs. biopsy. Sci Rep 2016;6:32286 doi:10.1038/srep32286 pmid:27574036

    CrossRefPubMed
17. 17.↵
    2. Thon N,
    3. Kreth FW,
    4. Tonn JC

    . The role of surgery in grade II/III oligodendroglial tumors. CNS Oncol 2015;4:317–23 doi:10.2217/cns.15.26 pmid:26478133

    CrossRefPubMed
18. 18.↵
    2. Jakola AS,
    3. Myrmel KS,
    4. Kloster R, et al

    . Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 2012;308:1881–88 doi:10.1001/jama.2012.12807 pmid:23099483

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Duffau H,
    3. Lopes M,
    4. Arthuis F, et al

    . Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985–96) and with (1996–2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry 2005;76:845–51 doi:10.1136/jnnp.2004.048520 pmid:15897509

    Abstract/FREE Full Text
20. 20.↵
    2. Wijnenga MM,
    3. French PJ,
    4. Dubbink HJ, et al

    . The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol 2018;20:103–12 doi:10.1093/neuonc/nox176 pmid:29016833

    CrossRefPubMed
21. 21.↵
    2. Eseonu CI,
    3. Eguia F,
    4. ReFaey K, et al

    . Comparative volumetric analysis of the extent of resection of molecularly and histologically distinct low grade gliomas and its role on survival. J Neurooncol 2017;134:65–74 doi:10.1007/s11060-017-2486-9 pmid:28527004

    CrossRefPubMed
22. 22.↵
    2. Capper D,
    3. Weissert S,
    4. Balss J, et al

    . Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010;20:245–54 doi:10.1111/j.1750-3639.2009.00352.x pmid:19903171

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Capper D,
    3. Zentgraf H,
    4. Balss J, et al

    . Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009;118:599–601 doi:10.1007/s00401-009-0595-z pmid:19798509

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Felsberg J,
    3. Wolter M,
    4. Seul H, et al

    . Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 2010;119:501–07 doi:10.1007/s00401-010-0647-4 pmid:20131059

    CrossRefPubMed
25. 25.↵
    2. Ahmadi R,
    3. Rezvan A,
    4. Dictus C, et al

    . Long-term outcome and survival of surgically treated supratentorial low-grade glioma in adult patients. Acta Neurochir (Wien) 2009;151:1359–65 doi:10.1007/s00701-009-0435-x pmid:19575144

    CrossRefPubMedWeb of Science
26. 26.↵
    2. McGirt MJ,
    3. Chaichana KL,
    4. Gathinji M, et al

    . Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 2009;110:156–62 doi:10.3171/2008.4.17536 pmid:18847342

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Yeh SA,
    3. Ho JT,
    4. Lui CC, et al

    . Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas. Br J Radiol 2005;78:230–35 doi:10.1259/bjr/28534346 pmid:15730987

    Abstract/FREE Full Text
28. 28.↵
    2. Kawaguchi T,
    3. Sonoda Y,
    4. Shibahara I, et al

    . Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neurooncol 2016;129:505–14 doi:10.1007/s11060-016-2201-2 pmid:27401154

    CrossRefPubMed
29. 29.↵
    2. Patel T,
    3. Bander ED,
    4. Venn RA, et al

    . The role of extent of resection in IDH1 wild-type or mutant low-grade gliomas. Neurosurgery 2018;82:808–14 doi:10.1093/neuros/nyx265 pmid:28945860

    CrossRefPubMed
30. 30.↵
    2. van den Bent MJ

    . Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol 2010;120:297–304 doi:10.1007/s00401-010-0725-7 pmid:20644945

    CrossRefPubMedWeb of Science